Matteo Samuele Pizzuto

Matteo Samuele Pizzuto

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Matteo Samuele Pizzuto

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Nature
Verified
Journal Article
Closed access
ECElisabetta Cameroni
Elisabetta Cameroni
JBJohn E. Bowen
John E. Bowen
LRLaura E. Rosen
Laura E. Rosen
CSChristian Saliba
Christian Saliba
SZSamantha K. Zepeda
Samantha K. Zepeda
DCDavide Corti
Davide Corti

1 April 2021 in Cell
Verified
Journal Article
Closed access
MMMatthew McCallum
Matthew McCallum
AMAnna De Marco
Anna De Marco
FLFlorian A. Lempp
Florian A. Lempp
MTM. Alejandra Tortorici
M. Alejandra Tortorici
DPDora Pinto
Dora Pinto
DVDavid Veesler
David Veesler

14 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
TSTyler N. Starr
Tyler N. Starr
NCNadine Czudnochowski
Nadine Czudnochowski
ZLZhuoming Liu
Zhuoming Liu
FZFabrizia Zatta
Fabrizia Zatta
YPYoung-Jun Park
Young-Jun Park
GSGyorgy Snell
Gyorgy Snell

20 November 2020 in Science
Verified
Journal Article
Open access
PDF file
MTM. Alejandra Tortorici
M. Alejandra Tortorici
MBMartina Beltramello
Martina Beltramello
FLFlorian A. Lempp
Florian A. Lempp
DPDora Pinto
Dora Pinto
HDHA DANG
HA DANG
DVDavid Veesler
David Veesler
A strong cocktail against SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by the trimeric spike protein that decorates the virus and binds the ACE2 receptor. Antibodies against the spike that neutralize viral infection have potential as therapeutics. Tortorici et al. describe two very potent antibodies, S2E12 and S2M11. Electron microscopy structures characterized the binding and showed that S2E12 traps the spike in a conformation that cannot bind ACE2. Both antibodies protected hamsters against SARS-CoV-2 challenge and may be useful in antibody cocktails to combat the virus and prevent the development of resistance. Science , this issue p. 950

6 August 2021 in Science
Verified
Journal Article
Open access
MMMatthew McCallum
Matthew McCallum
JBJessica Bassi
Jessica Bassi
AMAnna De Marco
Anna De Marco
ACAlex Chen
Alex Chen
AWAlexandra C. Walls
Alexandra C. Walls
DVDavid Veesler
David Veesler
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV

19 July 2021 in Nature
Verified
Journal Article
Open access
PDF file
MTM. Alejandra Tortorici
M. Alejandra Tortorici
NCNadine Czudnochowski
Nadine Czudnochowski
TSTyler N. Starr
Tyler N. Starr
RMRoberta Marzi
Roberta Marzi
AWAlexandra C. Walls
Alexandra C. Walls
MPMatteo Samuele Pizzuto
Matteo Samuele Pizzuto
The recent emergence of SARS-CoV-2 variants of concern1,2,3,4,5,6,7,8,9,10 and the recurrent spillovers of coronaviruses11,12 into the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift and that can prevent or treat future zoonotic infections. Here we describe a human monoclonal antibody designated S2X259, which recognizes a highly conserved cryptic epitope of the receptor-binding domain and cross-reacts with spikes from all clades of sarbecovirus. S2X259 broadly neutralizes spike-mediated cell entry of SARS-CoV-2, including variants of concern (B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429), as well as a wide spectrum of human and potentially zoonotic sarbecoviruses through inhibition of angiotensin-converting enzyme 2 (ACE2) binding to the receptor-binding domain. Furthermore, deep-mutational scanning and in vitro escape selection experiments demonstrate that S2X259 possesses an escape profile that is limited to a single substitution, G504D. We show that prophylactic and therapeutic administration of S2X259 protects Syrian hamsters (Mesocricetus auratus) against challenge with the prototypic SARS-CoV-2 and the B.1.351 variant of concern, which suggests that this monoclonal antibody is a promising candidate for the prevention and treatment of emergent variants and zoonotic infections. Our data reveal a key antigenic site that is targeted by broadly neutralizing antibodies and will guide the design of vaccines that are effective against all sarbecoviruses.